How to access Alecensa for ALK-positive non-small-cell lung cancer from Saudi Arabia: 2026 pathway via KFSHRC, KAMC, KFMC, and the wider kingdom oncology network
*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.
Saudi Arabia operates one of the deepest national oncology networks in the wider region. King Faisal Specialist Hospital and Research Centre in Riyadh and Jeddah (KFSHRC), King Abdulaziz Medical City Riyadh (KAMC) and the National Guard Health Affairs sites, King Fahad Medical City Riyadh (KFMC), Princess Noorah Oncology Centre Jeddah, and the Dr Sulaiman Al Habib oncology network all run medical and thoracic oncology services that diagnose, biomarker-test, and treat non-small-cell lung cancer (NSCLC) from first-line metastatic through later-line salvage. Alecensa (alectinib) is registered with the Saudi Food and Drug Authority (SFDA) and is the standard-of-care first-line ALK tyrosine kinase inhibitor at these centres for confirmed ALK-positive disease. For a Saudi patient with newly diagnosed metastatic NSCLC where the biopsy has returned an ALK rearrangement, or with stage IB to IIIA disease post-resection where the resected tissue confirms ALK positivity, the operational question is which prescribing centre fits the case, how the insurance and MoH pathway settles, and how the refill cycle integrates with a multi-year treatment course.
This page explains how the pathway works in 2026 for a Saudi-resident adult: who qualifies, where the diagnostic and molecular workup happens, where the prescription is written and filled, what the realistic out-of-pocket exposure band is in SAR, what to monitor on therapy, and how the treatment course fits into a Saudi family's life. It is concierge documentation written for a family already in conversation with a treating oncologist.
Why Alecensa, and why now
Alecensa is alectinib, a second-generation, central-nervous-system-penetrant ALK tyrosine kinase inhibitor developed by Roche in collaboration with Chugai Pharmaceutical. FDA approval came in December 2015 (post-crizotinib), full first-line approval in November 2017 based on the ALEX trial, and the April 2024 expansion to adjuvant treatment after complete resection of stage IB to IIIA ALK-positive NSCLC based on the ALINA trial. EMA approval followed parallel timing.
ALEX randomised 303 previously untreated ALK-positive metastatic NSCLC patients to Alecensa or crizotinib. Median progression-free survival was 34.8 months on Alecensa versus 10.9 months on crizotinib. Central-nervous-system objective response rate was 81 percent versus 50 percent for measurable baseline CNS metastases. Long-term follow-up shows 5-year overall survival of approximately 62 percent on first-line Alecensa.
ALINA randomised 257 patients with completely resected stage IB to IIIA ALK-positive NSCLC to two years of adjuvant Alecensa or platinum-based adjuvant chemotherapy. Disease-free survival hazard ratio was 0.24 favouring Alecensa. This is the basis for the new adjuvant indication and is increasingly the standard discussion for resected ALK-positive patients in MENA oncology practice.
What Alecensa is, in plain language
Alecensa is an oral capsule. Four 150 mg capsules per dose, twice daily, twelve hours apart, with food. Total daily dose 1,200 mg. Storage at room temperature; no refrigeration. There is no infusion, no inpatient stay, no certified-centre requirement. The prescribing oncologist writes the first prescription, the dispensing pharmacy fills the first 30-day or 60-day supply, and the patient takes Alecensa at home.
For metastatic disease, treatment continues until progression or intolerable toxicity. Median time on therapy in ALEX was 28.1 months. For the adjuvant indication, treatment is fixed at 2 years per the ALINA protocol.
The mechanism: ALK rearrangement produces a constitutively active fusion protein (most often EML4-ALK) that drives malignant transformation in bronchial epithelium. Alecensa binds the ATP-binding pocket of the ALK kinase domain with approximately 10-fold greater potency than crizotinib, achieves meaningful concentrations in the central nervous system because it is not a substrate of P-glycoprotein, and remains active against most kinase-domain resistance mutations that arise on crizotinib. Alecensa does not cover ALK G1202R; G1202R-mediated progression typically routes to lorlatinib.
The biomarker requirement
Alecensa is a targeted therapy. The eligibility gate is documented ALK rearrangement.
ALK testing in Saudi NSCLC is done by one or more of:
- Immunohistochemistry (IHC), typically using the Ventana ALK (D5F3) assay. This is the rapid, inexpensive screen. - Fluorescence in situ hybridisation (FISH): the traditional gold-standard test. - Next-generation sequencing (NGS) on tumour tissue or on circulating tumour DNA. NGS identifies the ALK rearrangement plus fusion partner, co-occurring driver mutations, and resistance mutations at progression.
Saudi-side molecular diagnostic capability is deepest at KFSHRC's molecular pathology service (which runs comprehensive solid-tumour NGS in-house and is one of the regional reference labs), KAMC, and KFMC pathology, with regional and international reference labs (Caris Life Sciences, Foundation Medicine) used for complex NGS work or liquid biopsy. If the original diagnostic biopsy did not include ALK testing, archived tissue submission to a reference lab or re-biopsy is the standard next step.
Eligibility at a Saudi oncologist's clinic
For Saudi-resident patients, the medical and thoracic oncology services apply the FDA, EMA, and major-guideline criteria with kingdom adaptation:
1. Histologically confirmed NSCLC (predominantly adenocarcinoma; squamous histology with ALK rearrangement is uncommon but possible). 2. Confirmed ALK rearrangement by IHC, FISH, or NGS. 3. For metastatic indication: stage IV disease confirmed by contrast CT chest/abdomen/pelvis, PET-CT, and brain MRI. 4. For adjuvant indication: stage IB (tumour 4 cm or larger) through IIIA disease with complete resection and confirmed ALK rearrangement on the resected specimen. 5. Baseline labs: complete blood count, comprehensive metabolic panel including LFTs, creatine kinase, bilirubin. 6. Baseline ECG with QTc and heart rate. 7. Baseline pulmonary assessment. 8. Pregnancy and lactation screen; contraception plan documented for women of reproductive potential. 9. Drug interaction screen including herbal products and food (grapefruit).
A Saudi patient should arrive at the oncology referral with the most recent pathology report, contrast CT or PET-CT, brain MRI, and any prior treatment history. Reserve Meds organises the documentation pack so the prescribing centre can confirm eligibility on the first review.
The Saudi prescribing and dispense picture, plainly
In 2026 the Saudi oncology centres with active Alecensa prescribing and refill experience include:
- King Faisal Specialist Hospital and Research Centre Riyadh, the kingdom's deepest comprehensive oncology and molecular diagnostics service. The KFSHRC thoracic oncology and molecular tumour board reviews all complex molecular-driver cases. KFSHRC Jeddah provides the parallel service in the western region. - King Abdulaziz Medical City Riyadh, the flagship National Guard Health Affairs site, with adult medical oncology services covering ALK-positive NSCLC. - King Fahad Medical City Riyadh, MoH flagship comprehensive oncology centre. - Princess Noorah Oncology Centre Jeddah, the dedicated MoH oncology centre in the western region. - Dr Sulaiman Al Habib oncology network (Riyadh, Khobar, Qassim, and other sites), the largest private-sector oncology footprint in the kingdom.
The pathway:
1. Diagnosis and molecular confirmation: at the diagnosing centre's pathology lab or sent to KFSHRC molecular pathology (a regional reference) or to an international reference lab. 2. Multidisciplinary tumour board review: KFSHRC, KAMC, KFMC, and Princess Noorah all run weekly thoracic or molecular tumour boards. The board documents the rationale and treatment plan. 3. Public-sector and MoH coverage: for Saudi nationals treated at KFSHRC, KAMC, KFMC, or other MoH-funded sites, Alecensa is dispensed through the institutional formulary and is covered as part of national oncology funding. The treatment-pathway approval runs through the prescribing centre's chemotherapy committee and the institutional pharmacy. 4. Private insurance pre-authorisation: for patients on private insurance (Bupa Arabia, Tawuniya, MedGulf, Allianz Saudi Fransi, AXA Cooperative) the documentation requirement is documented ALK rearrangement, MDT recommendation, and a clinical rationale letter. Pre-authorisation typically takes 5 to 14 days. 5. Pharmacy dispense: the prescribing centre's pharmacy (institutional or partnered specialty) fills a 30-day or 60-day supply. Roche Saudi Arabia's commercial supply runs through Cigalah, Banaja, and other regional distributors. 6. Refill cycle: monthly thereafter for the duration of treatment, with documentation of monitoring labs and response.
Cost expectation in SAR
US list price (2026) for Alecensa at the standard 600 mg twice-daily dose is approximately USD 14,000 to USD 16,000 per 30-day supply, with annual cost approximately USD 170,000 to USD 190,000. The 2-year adjuvant course at US WAC is approximately USD 340,000 to USD 380,000. Median time on first-line metastatic therapy in ALEX was 28.1 months.
At indicative 2026 cross rates, a single 30-day supply at USD 15,000 is approximately SAR 56,000, and annual cost at USD 180,000 is approximately SAR 675,000. A 2.5-year metastatic course is approximately SAR 1.69 million cumulative drug cost. The 2-year adjuvant course is approximately SAR 1.35 million.
For Saudi nationals treated at MoH or National Guard facilities, the institutional pathway typically covers Alecensa as part of the oncology formulary; out-of-pocket cost is minimal to zero. For patients in the private sector on commercial insurance, the cost falls under the insurance pre-authorisation process. For self-pay or partial-coverage families, the pharmacy issues a separated quote: drug cost, monitoring labs, imaging, oncologist visits, and any Reserve Meds coordination fee disclosed in writing.
Monitoring on therapy
- Liver function tests: every 2 weeks for the first 3 months, then monthly. Grade 1 to 2 elevations are common; grade 3 to 4 elevations trigger dose interruption per protocol. - Creatine kinase: every 2 weeks for the first month, then every 4 weeks or as clinically indicated. - Heart rate and ECG: as clinically indicated. Symptomatic bradycardia is uncommon and managed with dose reduction or interruption. - Pulmonary symptoms: new or worsening dyspnoea, cough, or fever triggers HRCT chest and pulmonology input. ILD on Alecensa is uncommon (under 1 percent) but is the toxicity requiring the most disciplined symptom awareness. - Photosensitivity counselling: sun avoidance and high-SPF sunscreen. Particularly salient in Saudi Arabia's UV-intense climate. - Disease assessment: contrast CT or PET-CT every 8 to 12 weeks for metastatic disease; brain MRI every 12 weeks if CNS metastases at baseline.
Religious, ethical, and family-logistics framing
Alecensa is an oral small molecule with no animal-source material in standard manufacturing, no donor cells, and no blood product. Halal acceptability is not in question. The classical Islamic jurisprudential framework for chronic medication in life-threatening illness already endorses the treatment shape.
The family-logistics burden sits in the chronicity and the discipline. A 1,200 mg total daily dose, twice daily with food, for two to three years (metastatic) or two years (adjuvant), with monitoring labs every two weeks for the first three months, requires a setup that the family can sustain. Medication diary, smartphone reminders, family member co-monitoring. For younger reproductive-age patients, contraception planning is documented before prescribing.
For working patients, the schedule integrates into standard workweek patterns. Monitoring lab visits and imaging cluster well around the existing oncology centre routines.
When Alecensa is not the right call
Alecensa is not appropriate for:
- ALK-negative disease. - Patients with a history of clinically significant interstitial lung disease. - Severe hepatic impairment (Child-Pugh C). - Pregnancy.
For confirmed ALK-positive disease where Alecensa is not the chosen first-line, the alternatives in 2026 are lorlatinib (third-generation, increasing first-line use based on the CROWN trial, particularly for CNS-heavy presentations and G1202R coverage) and brigatinib (second-generation alternative first-line). Crizotinib is rarely first-line in 2026. The clinical conversation with the treating oncologist about which TKI to start is the central decision.
Reserve Meds does not push a default. If the conversation with the treating oncologist points toward lorlatinib or brigatinib, the operational pathway shifts accordingly and we coordinate that pathway instead.
What Reserve Meds does on this case
We are a US-based concierge coordinator. We are not the prescriber and not the dispensing pharmacy. On a Saudi Alecensa case we build the document pack, submit first-review requests to the chosen prescribing centre, coordinate the insurance or MoH pre-authorisation pathway, set up the first dispense at the chosen pharmacy, and stay with the case through the refill cycle. Clinical decisions remain with your treating medical oncologist and the multidisciplinary tumour board.
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating medical oncologist and the multidisciplinary tumour board.
Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-05-20.